TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from CG Oncology, Inc. ( (CGON) ) is now available.
On November 10, 2025, Robert Lapetina resigned as interim principal financial and accounting officer of CG Oncology, Inc., effective November 30, 2025. Subsequently, on November 14, 2025, the company appointed Jim DeTore as the new interim principal financial and accounting officer, effective November 17, 2025. DeTore’s appointment comes through a consulting agreement with Monomoy Advisors, LLC, which stipulates a monthly payment structure and an initial engagement term of three months, with an option to extend. This leadership change is significant for CG Oncology as it navigates its financial and accounting operations, potentially impacting its strategic direction and stakeholder relations.
The most recent analyst rating on (CGON) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.
Spark’s Take on CGON Stock
According to Spark, TipRanks’ AI Analyst, CGON is a Neutral.
CG Oncology, Inc. is currently facing significant financial challenges, with no revenue and ongoing losses. The technical indicators suggest a bearish trend, and the valuation metrics highlight the company’s lack of profitability. The strong equity base and cash reserves provide some stability, but the overall outlook remains cautious due to the reliance on external funding and the need for revenue generation.
To see Spark’s full report on CGON stock, click here.
More about CG Oncology, Inc.
Average Trading Volume: 956,810
Technical Sentiment Signal: Buy
Current Market Cap: $3B
See more data about CGON stock on TipRanks’ Stock Analysis page.